Health Care Reform

This latest federal ruling strikes down the methodology insurers use to calculate "qualifying payment amount," which includes "rates for items and services that providers have no intention to provide," according to the ruling.

Even though six drug companies have filed lawsuits to halt the Medicare drug negotiation program, the companies have until Oct. 2 to present data on their drugs to CMS, which will make initial price offers in February.

Blood clot drugs Eliquis and Jardiance made the list, released on Tuesday, amid lawsuits filed by their manufacturers, attempting to block the government's effort to control drug prices.

Some physicians are lobbying CMS to bring down the hammer on the electronic payment fee scam.

Pharmaceutical manufacturers - many are attempting to block the federal government's effort to control drug prices - say the high costs support research and development and point out that Americans get new treatments first.

The Biden administration released draft guidance on a new program that allows Medicare prescription drug plan enrollees to pay out-of-pocket drug costs in monthly installments beginning in 2025.